Sugi Predict

Sugi Predict / Compounds / SCHEMBL147848

SCHEMBL147848

SCHEMBL147848

COc1ccc2c(O)ncnc2c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 8/20 0.54
▸ TRPA1 O75762 1/20 0.50
▸ CSF1R P07333 2/20 0.47
▸ TLR8 Q9NR97 1/20 0.47
▸ HTR1A P08908 2/20 0.46
▸ ADRA1D P25100 2/20 0.46
▸ ADRA1A P35348 2/20 0.46
▸ ADRA1B P35368 2/20 0.46
▸ PDE10A Q9Y233 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ GRM1 Q13255 1/20 0.45
▸ MTNR1A P48039 2/20 0.45
▸ MTNR1B P49286 2/20 0.45
▸ LCK P06239 2/20 0.43
▸ MAP4K4 O95819 1/20 0.43
▸ FERMT2 Q96AC1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28034141 0.98 EGFR (0.52) EGFRTRPA1CSF1RTLR8HTR1A
SCHEMBL28394647 0.86 MAPT (0.56) EGFRCSF1RMAPTGRM1MTNR1A
SCHEMBL23264581 0.82 KDR (0.54) EGFR
SCHEMBL14612883 0.80 KDR (0.44) EGFRMAPT
SCHEMBL8809617 0.80 CYP3A4 (0.44) CSF1RPDE10AMAPTMTNR1AMTNR1B
SCHEMBL13763602 0.80 TRPA1 (0.62) EGFRTRPA1CSF1RHTR1AADRA1D
SCHEMBL12143474 0.80 EGFR (0.55) EGFRTRPA1CSF1RTLR8HTR1A
SCHEMBL12844119 0.79 EGFR (0.51) EGFRTRPA1CSF1RHTR1AADRA1D
SCHEMBL20813459 0.79 EGFR (0.54) EGFRTRPA1CSF1RHTR1AADRA1D
SCHEMBL10975796 0.79 MAP4K4 (0.62) EGFRTRPA1HTR1AADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106068262-B Quinazoline derivant and preparation method thereof and application in medicine HAISCO PHARMACEUTICAL GROUP INC. (CN) 2019-10-29 — — CN disclosed
CN-109694356-A The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate 和记黄埔医药（上海）有限公司 2019-04-30 — — CN disclosed
CN-109694370-A The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate 和记黄埔医药（上海）有限公司 2019-04-30 — — CN disclosed
CN-109694355-A The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate 和记黄埔医药（上海）有限公司 2019-04-30 — — CN disclosed
US-9527885-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-27 — — US disclosed
US-9527885-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-27 — — US disclosed
US-9527885-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-27 — — US disclosed
EP-2909205-B1 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS BRISTOL MYERS SQUIBB CO (US) 2016-11-23 — — EP disclosed
EP-2909205-B1 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS BRISTOL MYERS SQUIBB CO (US) 2016-11-23 — — EP disclosed
US-9499550-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-11-22 — — US disclosed
WO-2012151195-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-08 — — WO disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 — — US disclosed
EP-2391602-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-12-07 — — EP disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
US-7700552-B2 Macrocyclic inhibitors of hepatitis C virus MEDIVIR AB (SE) 2010-04-20 — — US disclosed
US-7659245-B2 Macrocylic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD (IE) 2010-02-09 — — US disclosed
US-20090118312-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-05-07 — — US disclosed
US-20090023758-A1 Macrocyclic Inhibitors of Hepatitis C Virus MEDIVIR AB (SE) 2009-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023758-A1 Macrocyclic Inhibitors of Hepatitis C Virus CTRC, NOX3, HAVCR2 EGFR 1431/4885TRPA1 2931/4885CSF1R 3569/4885
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 EGFR 472/4885TRPA1 2023/4885CSF1R 652/4885
US-20090118312-A1 Macrocylic Inhibitors of Hepatitis C Virus CBR1, HAVCR2, AOC1 EGFR 1931/4885TRPA1 1960/4885CSF1R 2900/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 EGFR 472/4885TRPA1 2023/4885CSF1R 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.